Science and technology company, Merck, has opened its M Lab Collaboration Centre in the Songdo district of Incheon in South Korea.
The new collaboration centre replaces the company's smaller facility in Seoul and is staffed with more than 10 scientists and engineers. With the new centre, biopharmaceutical manufacturers in the country can now work closely with Merck's scientists and engineers to help solve their challenges and boost the development of their new therapies.
In line, the centre will include a simulated manufacturing environment and offer full end-to-end process development support. Customers will also be offered with education on best practices and new approaches in developing, optimising, scaling-up processes, and simplifying global technology transfer.
"With a rapidly growing biopharmaceutical industry in Korea and demand for novel and cost-effective therapies worldwide, there is a clear need for innovative concepts like our M Lab Collaboration Centres," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science, in a press release.
"At our new centre in Incheon, our customers will benefit from our deep technical expertise to develop processes for manufacturing drugs faster, safer and more effectively than ever before," Batra continued.
The new facility in Incheon is the ninth collaboration centre of Merck worldwide, with other located in North America, Brazil, France, China, Singapore, Japan, and Bangalore and Mumbai in India.
Sign up for CIO Asia eNewsletters.